Your Shopping Cart Is Empty
| Report Code: A13349 | Jan 2022 | Pages: 205 | ||
| Tables: 116 | Charts: 41 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Herpes Zoster Treatment Market
Request Now !The global herpes zoster treatment market size was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030. Herpes zoster, or shingles, is a common viral infection of the nerves caused by the varicella-zoster virus, which results in a painful rash of small blisters on a strip of skin anywhere on the body. Even after the rash is gone, the pain may continue for months. Shingles is more common in people with a depressed immune system and those over the age of 50. It's quite rare in children, and the symptoms are mild compared to what an adult may experience. After the person has had chicken pox, the virus lies dormant in certain nerves for years and its reactivation causes herpes zoster infection. herpes zoster is a sporadic disease with an estimated lifetime incidence of 10% to 20%. In addition, the incidence of herpes zoster increases sharply with advancing age, roughly doubling in each decade past the age of 50 years. Herpes zoster is uncommon in persons less than 15 years old.
Increase in the geriatric population coupled with rising incidence of herpes zoster is other factors that contribute toward the growth of the market. However, dearth of skilled professionals is expected to hinder the growth of the market. Conversely, increasing drug development provides lucrative growth opportunities to the market.
The global herpes zoster treatment market is segmented into treatment type, route of administration, distribution channel, and region. By treatment type, the market is categorized into antiviral medications, anti inflammatory medications, and others. On the basis of route of administration, it is segregated into oral and topical. Depending on distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which ranges from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
Almost every nation is dealing with the outbreak. Most markets are experiencing a decline, owing to the outbreak. The COVID-19 pandemic is an unprecedented global public health challenge, and is anticipated to have a negative impact on herpes zoster treatment market to the lockdowns that were imposed in the first half of 2020, which resulted in disruption of the supply chain. In addition, fall in number of surgeries and reduced patient visits to hospitals, owing to change in healthcare priorities and as a prevention measure to avoid contracting the disease also resulted in drop in number of patients visiting hospitals for diseases other than COVID-19.
Overall, the impact of the COVID-19 pandemic on the herpes zoster treatment market was reported to be negative. This was attributed to factors such as difficulty in management of diagnosis and treatment of herpes zoster, which require hospital stay, prolong recovery time in COVID-19 conditions and delay in treatment. However, this impact is expected to change post COVID-19 pandemic, and is expected to increase growth of the market.
Based on treatment type, the herpes zoster treatment market is categorized into antiviral medications, anti-inflammatory medications, and others. Presently, antiviral medication segment dominates the global market in 2020, and is anticipated to continue this trend during the forecast period. The key factors such as rise in demand for treatment of herpes zoster, and active government participation in immunization programs.
On the basis of route of administration, the market is segregated into oral, and topical. At present, the oral segment accounts for the majority of herpes zoster treatment market share, owing to rise in oral medication such as antiviral, anti-inflammatory, and other medication and is treated with oral, topical medications in both developed as well as developing countries, surge in demand of treatment, and surge in geriatric population.
On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. the drug stores & retail pharmacies segment accounts for the majority of herpes zoster treatment market share, owing to rise in diagnosis of infections, increasing awareness about the use of herpes zoster drugs, and an increase in the adoption of herpes zoster treatment. In addition, increase in government initiatives to promote healthy lifestyle drives the growth of the market.
By region, the herpes zoster treatment market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This was attributed to increase in geriatric population, rise in patient awareness towards treatment of herpes zoster, surge in demand drug therapies, availability of advanced healthcare facilities with trained medical professionals, presence of key players in the region, and surge in investment made by governments in the healthcare system.
Key Benefits For Stakeholders
Herpes Zoster Treatment Market Report Highlights
| Aspects | Details |
|---|---|
| By Treatment Type |
|
| By Route of Administration |
|
| By Distribution Channel |
|
| By Region |
|
| By Key Market Players |
|
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Driver
3.5.1.1.Increase in geriatric population, coupled with rise in incidences of herpes zoster
3.5.2.Restraint
3.5.2.1.Dearth of skilled professionals
3.5.3.Opportunities
3.5.3.1.R&D investments by pharmaceutical companies
3.5.4.Impact analysis
3.6.COVID-19 Impact Analysis on Herpes Zoster Treatment Market
CHAPTER 4:HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Antiviral medications
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Anti-inflammatory medications
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Others
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1.Overview
5.1.1.Market size and forecast, by region
5.2.Oral
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Topical
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug stores & retail pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online providers
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:HERPES ZOSTER TREATMENT MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.3.North America market size and forecast, By Route of administration
7.2.4.North America market size and forecast, by Distribution Channel
7.2.5.1.U.S
7.2.5.1.1.U.S. Herpes Zoster Treatment market, by Treatment Type
7.2.5.1.2.U.S. Herpes Zoster Treatment market, By Route of administration
7.2.5.1.3.U.S. Herpes Zoster Treatment market, by Distribution Channel
7.2.5.2.Canada
7.2.5.2.1.Canada Herpes Zoster Treatment market, by Treatment Type
7.2.5.2.2.Canada Herpes Zoster Treatment market, By Route of administration
7.2.5.2.3.Canada Herpes Zoster Treatment market, by Distribution Channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico Herpes Zoster Treatment market, by Treatment Type
7.2.5.3.2.Mexico Herpes Zoster Treatment market, By Route of administration
7.2.5.3.3.Mexico Herpes Zoster Treatment market, by Distribution Channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe market size and forecast, by Treatment Type
7.3.3.Europe market size and forecast, By Route of administration
7.3.4.Europe market size and forecast, by Distribution Channel
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany Herpes Zoster Treatment market, by Treatment Type
7.3.5.1.2.Germany Herpes Zoster Treatment market, By Route of administration
7.3.5.1.3.Germany Herpes Zoster Treatment market, by Distribution Channel
7.3.5.2.France
7.3.5.2.1.France Herpes Zoster Treatment market, by Treatment Type
7.3.5.2.2.France Herpes Zoster Treatment market, By Route of administration
7.3.5.2.3.France Herpes Zoster Treatment market, by Distribution Channel
7.3.5.3.UK
7.3.5.3.1.UK Herpes Zoster Treatment market, by Treatment Type
7.3.5.3.2.UK Herpes Zoster Treatment market, By Route of administration
7.3.5.3.3.UK Herpes Zoster Treatment market, by Distribution Channel
7.3.5.4.Italy
7.3.5.4.1.Italy Herpes Zoster Treatment market, by Treatment Type
7.3.5.4.2.Italy Herpes Zoster Treatment market, By Route of administration
7.3.5.4.3.Italy Herpes Zoster Treatment market, by Distribution Channel
7.3.5.5.Spain
7.3.5.5.1.Spain Herpes Zoster Treatment market, by Treatment Type
7.3.5.5.2.Spain Herpes Zoster Treatment market, By Route of administration
7.3.5.5.3.Spain Herpes Zoster Treatment market, by Distribution Channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe Herpes Zoster Treatment market, by Treatment Type
7.3.5.6.2.Rest of Europe Herpes Zoster Treatment market, By Route of administration
7.3.5.6.3.Rest of Europe Herpes Zoster Treatment market, by Distribution Channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific market size and forecast, by Treatment Type
7.4.3.Asia-Pacific market size and forecast, By Route of administration
7.4.4.Asia-Pacific market size and forecast, by Distribution Channel
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan Herpes Zoster Treatment market, by Treatment Type
7.4.5.1.2.Japan Herpes Zoster Treatment market, By Route of administration
7.4.5.1.3.Japan Herpes Zoster Treatment market, by Distribution Channel
7.4.5.2.China
7.4.5.2.1.China Herpes Zoster Treatment market, by Treatment Type
7.4.5.2.2.China Herpes Zoster Treatment market, By Route of administration
7.4.5.2.3.China Herpes Zoster Treatment market, by Distribution Channel
7.4.5.3.Australia
7.4.5.3.1.Australia Herpes Zoster Treatment market, by Treatment Type
7.4.5.3.2.Australia Herpes Zoster Treatment market, By Route of administration
7.4.5.3.3.Australia Herpes Zoster Treatment market, by Distribution Channel
7.4.5.4.India
7.4.5.4.1.India Herpes Zoster Treatment market, by Treatment Type
7.4.5.4.2.India Herpes Zoster Treatment market, By Route of administration
7.4.5.4.3.India Herpes Zoster Treatment market, by Distribution Channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea Herpes Zoster Treatment market, by Treatment Type
7.4.5.5.2.South Korea Herpes Zoster Treatment market, By Route of administration
7.4.5.5.3.South Korea Herpes Zoster Treatment market, by Distribution Channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific Herpes Zoster Treatment market, by Treatment Type
7.4.5.6.2.Rest of Asia-Pacific Herpes Zoster Treatment market, By Route of administration
7.4.5.6.3.Rest of Asia-Pacific Herpes Zoster Treatment market, by Distribution Channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA market size and forecast, by Treatment Type
7.5.3.LAMEA market size and forecast, By Route of administration
7.5.4.LAMEA market size and forecast, by Distribution Channel
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil Herpes Zoster Treatment market, by Treatment Type
7.5.5.1.2.Brazil Herpes Zoster Treatment market, By Route of administration
7.5.5.1.3.Brazil Herpes Zoster Treatment market, by Distribution Channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia Herpes Zoster Treatment market, by Treatment Type
7.5.5.2.2.Saudi Arabia Herpes Zoster Treatment market, By Route of administration
7.5.5.2.3.Saudi Arabia Herpes Zoster Treatment market, by Distribution Channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa Herpes Zoster Treatment market, by Treatment Type
7.5.5.3.2.South Africa Herpes Zoster Treatment market, By Route of administration
7.5.5.3.3.South Africa Herpes Zoster Treatment market, by Distribution Channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA herpes zoster treatment market, by Treatment Type
7.5.5.4.2.Rest of LAMEA Herpes Zoster Treatment market, By Route of administration
7.5.5.4.3.Rest of LAMEA Herpes Zoster Treatment market, by Distribution Channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES.
8.1.1.Company overview
8.1.2.Operating business segment
8.1.3.Product portfolio
8.1.4.Business performance
8.2.BAUSCH HEALTH COMPANIES INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.CAMBER PHARMACEUTICALS
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.CIPLA INC.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance.
8.5.ELI LILLY AND COMPANY
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.GLAXOSMITHKLINE PLC (GSK)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance.
8.7.MERCK & COMPANY INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.NOVARTIS INTERNATIONAL AG (SANDOZ)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.TEVA PHARMACEUTICALS
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 02.ANTIVIRAL MEDICATION HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 03.ANTI-INFLAMMATORY MEDICATIONS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.OTHERS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.ROUTE OF ADMINISTRATION HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 06.ORAL HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.TOPICAL HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 08.GLOBAL HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 09.HOSPITAL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 10.DRUG STORES & RETAIL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11.ONLINE PROVIDERS DISTRIBUTION CHANNELS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12.HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 17.U.S. HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 18.U.S. HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 19.RETAIL PHARMACIES AND HOSPITAL PHARMACIES SEGMENT COLLECTIVELY U.S. HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 20.CANADA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 21.CANADA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 22.CANADA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 23.MEXICO HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 24.MEXICO HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 25.MEXICO HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26.EUROPE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 27.EUROPE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 28.EUROPE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 29.EUROPE HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 30.GERMANY HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 31.GERMANY HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 32.GERMANY HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 33.FRANCE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 34.FRANCE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 35.FRANCE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 36.UK HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 37.UK HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 38.UK HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.ITALY HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 40.ITALY HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 41.ITALY HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 42.SPAIN HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 43.SPAIN HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 44.SPAIN HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 49.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 51.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 52.JAPAN HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 53.JAPAN HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 54.JAPAN HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 55.CHINA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 56.CHINA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 57.CHINA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 59.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 61.INDIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 62.INDIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 63.INDIA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 64.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 65.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 70.LAMEA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 71.LAMEA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 72.LAMEA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 73.LAMEA HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 74.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 75.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 76.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 77.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 78.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 80.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 81.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 83.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 84.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 86.ABBOTT: COMPANY SNAPSHOT
TABLE 87.ABBOTT: OPERATING SEGMENT
TABLE 88.ABBOTT: PRODUCT PORTFOLIO
TABLE 89.BAUSCH: COMPANY SNAPSHOT
TABLE 90.BAUSCH: OPERATING SEGMENTS
TABLE 91.BAUSCH: PRODUCT PORTFOLIO
TABLE 92.CAMBER: COMPANY SNAPSHOT
TABLE 93.CAMBER: OPERATING SEGMENTS
TABLE 94.CAMBER: PRODUCT PORTFOLIO
TABLE 95.CAMBER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96.CIPLA: COMPANY SNAPSHOT
TABLE 97.CIPLA: OPERATING SEGMENTS
TABLE 98.CIPLA: PRODUCT PORTFOLIO
TABLE 99.LILLY: COMPANY SNAPSHOT
TABLE 100.LILLY: OPERATING SEGMENTS
TABLE 101.LILLY: PRODUCT PORTFOLIO
TABLE 102.GSK: COMPANY SNAPSHOT
TABLE 103.GSK: OPERATING SEGMENTS
TABLE 104.GSK: PRODUCT PORTFOLIO
TABLE 105.MERCK: COMPANY SNAPSHOT
TABLE 106.MERCK: OPERATING SEGMENTS
TABLE 107.MERCK: PRODUCT PORTFOLIO
TABLE 108.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 109.NOVARTIS: OPERATING SEGMENTS
TABLE 110.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 111.PFIZER: COMPANY SNAPSHOT
TABLE 112.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 113.PFIZER: PRODUCT PORTFOLIO
TABLE 114.TEVA: COMPANY SNAPSHOT
TABLE 115.TEVA: OPERATING SEGMENTS
TABLE 116.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL HERPES ZOSTER TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.HIGH THREAT OF SUBSTITUTES
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.HIGH INTENSITY OF RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF ANTIVIRAL MEDICATION HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF ANTI-INFLAMMATORY MEDICATIONS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF OTHERS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF ORAL HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF TOPICAL HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES & RETAIL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PROVIDERS DISTRIBUTION CHANNELS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.ABBOTT: NET SALES, 2020 ($MILLION)
FIGURE 19.ABBOTT: REVENUE SHARE PER SEGMENT 2020(%)
FIGURE 20.ABBOTT: REVENUE SHARE, BY REGION 2020(%)
FIGURE 21.BAUSCH: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.BAUSCH: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 23.BAUSCH: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 24.CIPLA: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.CIPLA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 26.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 28.LILLY: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 29.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.GSK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.MERCK: REVENUE SHARE, BY PRODUCT, 2020 (%)
FIGURE 34.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.TEVA.: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.TEVA: REVENUE SHARE, BY REGION, 2020 (%)
This section provides opinions of top level analyst in the herpes zoster treatment market. According to analyst, substantial increase in research and development activities, availability of effective drugs, increase in government support for various vaccinations, awareness programs and funds provided by them, and increasing geriatric population drives growth of the herpes zoster treatment market.
As per analyst, increase in patient awareness toward drug therapies, rise in prevalence rate of shingles in older population, and predominance of effective antibodies are the prime reasons that drive growth of the herpes zoster treatment market. Furthermore, dearth of skilled professionals is expected to hinder growth of the market. Moreover, increase in drug development provides lucrative growth opportunities to the market.
They further added that North America is expected to remain dominant during the forecast period, owing to increase in demand for herpes zoster treatment, surge in demand for drug therapies, availability of advanced healthcare facilities with trained medical professionals, presence of key players in the region, surge in investments made by governments in the healthcare system, and presence of major key players in this region. Moreover, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period, owing to increase in number of hospitals and diagnosis centers with advanced medical facilities along with surge in availability of advanced herpes zoster treatment.
A. The total market value of herpes zoster treatment market is $217.09 million in 2020.
A. The forecast period for herpes zoster treatment market is 2021 to 2030
A. The market value of herpes zoster treatment market in 2021 is $224.90 million.
A. The base year is 2020 in herpes zoster treatment market
A. Top companies such as Abbott Laboratory, Bausch Health, Cipla Inc., Camber Pharmaceuticals, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd
A. Antiviral medication segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to rise in demand for treatment of herpes zoster and active government participation in immunization programs.
A. Increase in geriatric population, coupled with rising incidences of herpes zoster is anticipated to drive the market in the forecast period.
A. North America is projected to account for a major share of the global herpes zoster treatment market during the forecast period. U.S. holds the major share due to increase in geriatric population, rise in patient awareness toward treatment of herpes zoster, surge in demand drug therapies, availability of advanced healthcare facilities with trained medical professionals, presence of key players in the country.
Start reading instantly.
This Report and over 67,092+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report